Welcome to our dedicated page for AUTOLUS THERAPEUTICS news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS stock.
Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics plc (Nasdaq: AUTL) announced new preclinical data on its programmed T cell therapies at the AACR Virtual Annual Meeting II, scheduled for June 22-24, 2020. Key presentations include AUTO5 targeting T cell lymphoma, AUTO6NG for small cell lung cancer, and AUTO7 for advanced prostate cancer. Oral and poster presentations will showcase the advancements and efficacy of these therapies. A conference call to discuss the findings will be held on June 25, 2020, at 8:30 am EDT. These developments highlight Autolus's commitment to innovative cancer treatments.
Summary not available.